Royce & Associates LP decreased its position in RadNet, Inc. (NASDAQ:RDNT – Free Report) by 6.0% during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 198,494 shares of the medical research company’s stock after selling 12,775 shares during the quarter. Royce & Associates LP’s holdings in RadNet were worth $13,684,000 at the end of the most recent reporting period.
Several other large investors have also made changes to their positions in the company. Diversified Trust Co bought a new position in RadNet during the 3rd quarter valued at about $361,000. Maryland State Retirement & Pension System boosted its position in RadNet by 52.9% in the third quarter. Maryland State Retirement & Pension System now owns 15,742 shares of the medical research company’s stock valued at $1,085,000 after buying an additional 5,449 shares in the last quarter. Lisanti Capital Growth LLC acquired a new position in RadNet in the third quarter valued at about $2,342,000. Illinois Municipal Retirement Fund grew its stake in RadNet by 10.6% during the third quarter. Illinois Municipal Retirement Fund now owns 38,835 shares of the medical research company’s stock worth $2,677,000 after buying an additional 3,732 shares during the last quarter. Finally, Keybank National Association OH grew its stake in RadNet by 438.7% during the third quarter. Keybank National Association OH now owns 81,935 shares of the medical research company’s stock worth $5,649,000 after buying an additional 66,726 shares during the last quarter. Institutional investors own 77.90% of the company’s stock.
Insiders Place Their Bets
In other RadNet news, EVP Mital Patel sold 44,661 shares of the business’s stock in a transaction dated Wednesday, November 11th. The shares were sold at an average price of $78.51, for a total value of $3,506,335.11. Following the completion of the transaction, the executive vice president directly owned 155,514 shares of the company’s stock, valued at approximately $12,209,404.14. The trade was a 22.31% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 5.14% of the company’s stock.
RadNet Stock Performance
RadNet (NASDAQ:RDNT – Get Free Report) last released its quarterly earnings results on Sunday, November 8th. The medical research company reported $0.30 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.22 by $0.08. RadNet had a positive return on equity of 3.14% and a negative net margin of 0.94%. The business had revenue of $638.26 million during the quarter, compared to analysts’ expectations of $639.97 million. During the same period in the previous year, the business posted $0.20 earnings per share. The firm’s revenue for the quarter was up 22.1% compared to the same quarter last year. On average, equities research analysts predict that RadNet, Inc. will post 0.56 EPS for the current fiscal year.
Wall Street Analysts Forecast Growth
Several analysts have recently weighed in on RDNT shares. Barclays raised their price objective on shares of RadNet from $65.00 to $79.00 and gave the stock an “overweight” rating in a report on Friday, August 28th. Truist Financial lifted their target price on shares of RadNet from $90.00 to $94.00 and gave the company a “buy” rating in a research note on Tuesday, August 11th. KeyCorp boosted their target price on RadNet from $92.00 to $95.00 and gave the stock an “overweight” rating in a report on Tuesday, November 10th. Jefferies Financial Group restated a “buy” rating on shares of RadNet in a research report on Friday, July 31st. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of RadNet in a research report on Wednesday, November 4th. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, RadNet currently has an average rating of “Moderate Buy” and an average price target of $89.67.
Read Our Latest Research Report on RDNT
RadNet Company Profile
RadNet, Inc. operates outpatient diagnostic imaging centers in the United States. Its centers provide services including magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), mammography, ultrasound, X-ray and nuclear medicine imaging. The company serves patients, physicians and healthcare organizations, with operations across several states, including California, Delaware, Florida, Maryland, New Jersey and New York. Its imaging centers offer diagnostic services for a range of medical needs, from routine screening to specialized examinations.
Read More
- Five stocks we like better than RadNet
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Want to see what other hedge funds are holding RDNT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for RadNet, Inc. (NASDAQ:RDNT – Free Report).
Receive News & Ratings for RadNet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RadNet and related companies with MarketBeat.com's FREE daily email newsletter.
